Company: CWAN
Filing Date: 2025-04-21
Form Type: S-8
Source: 0001193125-25-087339
Chunk: 1

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-04-21
Form: S-8
Chunk 1
---
2025 (the “Merger Agreement”), by
and among Clearwater Analytics Holdings, Inc., a Delaware corporation (the “Company”), Poseidon Acquirer, Inc., a Delaware corporation and a direct, wholly-owned subsidiary of the Company (“Acquirer”), Poseidon Merger Sub I,
Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”), Poseidon Merger Sub II, LLC, a Delaware limited liability company and an indirect subsidiary of the Company (“Merger Sub II”), Enfusion,
Inc., a Delaware corporation (“Enfusion”), and Enfusion Ltd. LLC, a Delaware limited liability company and subsidiary of Enfusion (“Enfusion Operating Company”), (i) Merger Sub II merged with and into Enfusion Operating Company
(the “LLC Merger”), with Enfusion Operating Company surviving the LLC Merger as a wholly-owned subsidiary of the Company; (ii) Merger Sub merged with and into Enfusion (the “Merger”), with Enfusion surviving the Merger as an
indirectly wholly-owned subsidiary of the Company (the “Surviving Corporation”); and (iii) the Surviving Corporation merged with and into Acquirer (the “Second Merger”, and together with the Merger, the “Corporate
Mergers”, and the Corporate Mergers together with the LLC Merger, the “Mergers”), with Acquirer surviving the Second Merger as a wholly-owned subsidiary of the Company.

This registration statement on Form S-8 (this “registration statement”) registers the
offer and sale of (i) up to 1,978,134 shares of Class A common stock, par value $0.001 per share, of the Company (the “Class A Common Stock”) issuable to holders of certain restricted stock units granted under the Enfusion 2021
Stock Option and Incentive Plan (the “Enfusion Plan”) that were converted, as described below, into restricted stock units of the Company in connection with the consummation of the Mergers; and (ii) up to 11,061,379 shares of Class A
Common Stock issuable from time to time under the Enfusion Plan, which was assumed by the Company in accordance with the terms of the Merger Agreement and represents the product of the number of shares of Enfusion Class A Common Stock, par
value $0.001 per share (the “Enfusion Class A Common Stock”), that remained available for issuance under the Enfusion Plan immediately prior to